Ovid Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview

Ovid Therapeutics

08/03/2024 12:38

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 11
(estimated) for the period ending December 31 2023
    * The New York City-based  company is expected to report a
22.1% increase in revenue to $56.5 thousand from $46.28 thousand
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Ovid Therapeutics Inc is
for a
loss of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $7.00​, above​ its last closing price of $3.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.19       -0.19      -0.16     Beat    15.2
 Jun. 30 2023  -0.20       -0.20      -0.18     Beat    12
 Mar. 31 2023  -0.17       -0.17      -0.19     Missed  -10.9​
 Dec. 31 2022  -0.17       -0.18      -0.16     Beat    12.2
 ​​Sep.        -0.21       -0.21      -0.17     Beat    20.7
 30 2022                                                
 Jun. 30 2022  -0.25       -0.25      -0.21     Beat    15.6​
 Mar. 31 2022  -0.20       -0.21      -0.23     Missed  -11
 Dec. 31 2021  -0.15       -0.16      -0.10     Beat    38
 This summary was machine generated March 8 at 12:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)